St Chaffrey, France

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Clinical Studies for the Treatment of Advanced Solid Tumors

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Primary objective: to evaluate the efficacy of RC148 injection as monotherapy or combination therapy in patients locally advanced or metastatic non-small cell lung cancer;

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent. Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.

Ischemic Stroke Nutrition Intervention Study

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

The design of dose level and Cohorts: Phase Ib: Advanced Non-sq-NSCLC(dose escalation phase): The dose level of HB0025 including the following leves, the dose of chemotherapy is fixed(Pemetrexed 500 mg/m² iv d1+Carboplatin AUC 5 iv d1) in the study. dose 1: 10mg/kg, dose 2: 20mg/kg, dose -1: 6mg/kg, dose +1: 15mg/kg, dose +2: 30mg/kg. Advanced EC and sq-NSCLC: With the same dose level design above, HB0025 combined with Paclitaxel(175 mg/m² iv d1) and Carboplatin(AUC 5 iv d1) in the treatment of advanced EC and sq-NSCLC. Phase II: Advanced non-small cell lung cancer indications: 1. Cohort 1: Patients with recurrent, metastatic, locally advanced non-squamous non-small cell lung cancer (Non-sq-NSCLC) who have not received systemic anti-tumor treatment and do not carry EGFR sensitive mutations or ALK fusion gene sensitive mutations; HB0025 at 10mg/kg combined with Pemetrexed 500 mg/m² iv d1 + Carboplatin AUC 5 iv d1; expended to approximately 40 subjects. 2. Cohort 2: Patients with recurrent, metastatic, locally advanced Non-sq-NSCLC who have not received systemic anti-tumor treatment and do not carry EGFR sensitive mutations or ALK fusion gene sensitive mutations; HB0025 at 20mg/kg combined with the same dose as cohort 1; expended to approximately 40 subjects. 3. Cohort 3: Patients with recurrent, metastatic, locally advanced squamous non-small cell lung cancer (Sq-NSCLC) who have not received systemic anti-tumor treatment and do not carry EGFR sensitive mutations or ALK fusion gene sensitive mutations; HB0025 at 10mg/kg combined with Paclitaxel 175mg/m² iv d1 + Carboplatin AUC 5 iv d1; expanded to approximately 40 subjects. 4. Cohort 4: Patients with recurrent, metastatic, locally advanced Sq-NSCLC who have not received systemic anti-tumor treatment and do not carry EGFR sensitive mutations or ALK fusion gene sensitive mutations; HB0025 at 20 mg/kg combined with the same dose as Cohort 3; extended to approximately 40 subjects. Advanced endometrial cancer indications: 1. Cohort 1: Patients with recurrent, metastatic, locally advanced endometrial cancer who have not received systemic anti-tumor treatment before; HB0025 at 10 mg/kg combined with Paclitaxel 175 mg/m² iv d1 + Carboplatin AUC 5 iv d1; expanded to approximately 40 subjects. 2. Cohort 2: Patients with recurrent, metastatic, locally advanced endometrial cancer who have not received systemic anti-tumor treatment before; HB0025 at 20mg/kg combined with chemotherapy as the same dose as Chort1; expanded to approximately 40 cases.

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments